Background Uropathogenic Escherichia coli (UPEC) is the most important pathogen involved in urinary tract infections (UTIs). Beta-lactam antibiotics have been widely used to treat UPEC infections; however, extended-spectrum beta-lactamases (ESBLs) create significant therapeutic problems by inactivating almost all beta-lactams except cephamycins and carbapenems [1,2]. The CTX-M-type beta-lactama...

Extended spectrum beta lactamases (ESBLs) continue to be a major problem in clinical setups world over, conferring resistance to the expanded spectrum cephalosporins. An attempt was made to study ESBL production among Enterobacteriaceae members from a tertiary care center in Chennai. A total of seventy randomly collected isolates of the family Enterobacteriaceae from a tertiary care center was ...

Emergence of extended spectrum β lactamases (ESBLs) producing strains of gram negative bacteria, as one of the leading cause of septicemia often complicates the clinical and therapeutic outcome. The present study was undertaken to investigate the prevalence of ESBLs in bacteria isolated from neonatal septicemia cases along with their antimicrobial sensitivity pattern. Blood samples were collect...

Extended spectrum beta-lactamases (ESBLs) are defined as enzymes produced by certain bacteria that are able to hydrolyze extended spectrum cephalosporin. They are therefore effective against beta-lactam antibiotics such as ceftazidime, ceftriaxone, cefotaxime and oxyimino-monobactam. The objective of the current review is to provide a better understanding of ESBL and the epidemiology of ESBL pr...

BACKGROUND Simultaneous resistance to aminoglycosides and fluoroquinolones in carbapeneme non-susceptible (CNS) isolates will inevitably create problems. The present study was performed to characterize the prevalence of the plasmid-mediated quinolone resistance determinants (QRDs) and aminoglycoside resistance determinants (ARDs) among the CNS Enterobacter cloacae (E. cloacae) isolates in a Chi...

BACKGROUND The treatment of complicated urinary tract infections may require the use of a parenteral antibiotic with potent activity against the most common urinary pathogens. Ertapenem is a broad-spectrum 1beta-methyl carbapenem with a long plasma half-life that allows administration of a single daily dose. METHODS The purpose of this work was to test the in vitro susceptibility to ertapenem...

www.expert-reviews.com ISSN 1478-7210 © 2008 Expert Reviews Ltd 10.1586/14787210.6.5.671 The potential options available for treating serious infections caused by enterobacteria include penicillins (with or without β-lactamase inhibitors), cephalosporins, aztreonam, carbapenems, fluoroquinolones and, in certain situations only, aminoglycosides and colistin. Recently, tigecycline has been added ...

BACKGROUND Extended Spectrum beta-Lactamases (ESBLs)-producing strains of Enterobacteriaceae have emerged as a major problem in hospitalized as well as community based patients. Infections due to ESBLs-producers range from uncomplicated urinary tract infection to life threatening sepsis. The objective of this study was to find out the prevalence of ESBLs-producing Gram- negative bacilli among c...

Objective(s) Production of extended-spectrum beta-lactamases (ESBLs) by enteric bacteria continues to be a major problem in hospitals and community. ESBLs producing bacteria cause many serious infections including urinary tract infections, peritonitis, cholangitis and intra-abdominal abscess. The aim of this study was to determine the prevalence of ESBLs producing Escherichia coli and Klebsiel...

Extended-spectrum beta-lactamases (ESBLs) efficiently hydrolyze extended-spectrum beta-lactams such as cefotaxime, ceftriaxone, ceftazidime, and aztreonam. ESBLs are most often plasmid-mediated. In Taiwan, the prevalence of ESBLs in bacteria has risen, ranging from 8.5 to 29.8% in Klebsiella pneumoniae and 1.5 to 16.7% in Escherichia coli isolates. The most prevalent types of ESBLs are SHV-5, S...